Urolithiasis Management Devices Market by Type (Extracorporeal Shock Wave Lithotripsy, Ureteroscopy, Percutaneous Nephrolithotomy), by Application (Kidney Stones, Bladder Stones), by End-Use Industry (Hospitals, Clinics, Ambulatory Surgical Centers), and by Region; Insights & Forecast (2024 – 2030)

As per Intent Market Research, the Urolithiasis Management Devices Market was valued at USD 3.0 Billion in 2024-e and will surpass USD 4.8 Billion by 2030; growing at a CAGR of 8.4% during 2025 - 2030.

Urolithiasis, the condition of having kidney stones or bladder stones, is one of the most common urinary tract disorders affecting millions of people globally. Effective management of urolithiasis is crucial for preventing complications like infection, urinary tract obstruction, and kidney damage. The market for urolithiasis management devices is expanding due to an increase in the prevalence of kidney and bladder stones, particularly in regions with high rates of obesity, dehydration, and dietary factors. These devices play a critical role in non-invasive and minimally invasive treatment methods, improving patient outcomes by efficiently managing stone removal and fragmentation. The increasing awareness of stone-related diseases and technological advancements in urolithiasis management are propelling the market forward.

The primary devices used for the management of urolithiasis include Extracorporeal Shock Wave Lithotripsy (ESWL), Ureteroscopy, and Percutaneous Nephrolithotomy (PCNL). These devices aim to break down stones or facilitate their removal, reducing the need for more invasive surgical procedures. The market is categorized based on the type of device, application, and end-use industry. Hospitals, clinics, and ambulatory surgical centers are the primary end-users of these devices. Advancements in minimally invasive technologies and the rising number of patients seeking less painful treatment options are driving the growth of this market.

ESWL is Largest Segment Due to Non-Invasive Nature

Extracorporeal Shock Wave Lithotripsy (ESWL) is the largest segment in the urolithiasis management devices market, primarily due to its non-invasive nature and effectiveness in treating kidney stones. ESWL uses focused shock waves to break kidney stones into smaller fragments, which can then be passed out of the body through the urinary tract. This method is preferred by both healthcare providers and patients because it does not require any incisions, reducing the risk of infection and recovery time. It is particularly effective for smaller to medium-sized stones located in the kidney or upper urinary tract, making it a first-line treatment option in many clinical settings.

The non-invasive nature of ESWL has made it highly popular, especially in developed countries where advanced healthcare technologies are more accessible. It is cost-effective, reduces the need for extended hospital stays, and allows patients to resume normal activities relatively quickly. As the global incidence of kidney stones rises, ESWL is expected to maintain its dominant position in the market, with a growing number of hospitals and clinics adopting it as their preferred treatment method for urolithiasis.

Ureteroscopy is Fastest Growing Segment Due to Advancements in Technology

Ureteroscopy is the fastest growing segment in the urolithiasis management devices market, driven by advancements in technology and its ability to treat stones located in the lower urinary tract, including the bladder and ureter. Ureteroscopy involves the insertion of a thin, flexible tube with a camera to directly visualize the stone and remove it either through fragmentation or retrieval. This method is minimally invasive, allowing patients to recover quickly with reduced pain compared to traditional surgical procedures. Ureteroscopy is especially beneficial for treating larger stones or stones that are difficult to reach with non-invasive methods like ESWL.

The increasing adoption of flexible ureteroscopes, which provide enhanced visualization and precision, is fueling the growth of this segment. Additionally, ureteroscopy is being increasingly used in outpatient settings due to its reduced recovery time and ability to treat a variety of stone sizes. As more hospitals and clinics invest in state-of-the-art ureteroscopy equipment, the segment is expected to continue its rapid growth, driven by its efficiency and the demand for minimally invasive treatment options for urolithiasis.

Hospitals Are Largest End-Use Industry Due to High Patient Volume

Hospitals are the largest end-use industry for urolithiasis management devices, due to their capacity to handle a high volume of patients requiring treatment for kidney and bladder stones. Hospitals are equipped with the necessary infrastructure, including advanced diagnostic tools, surgical theaters, and specialized medical teams, to perform procedures like ESWL, ureteroscopy, and PCNL. As urolithiasis is a common condition that affects millions worldwide, hospitals play a central role in providing treatment to patients suffering from stone-related disorders.

Hospitals also offer a broader range of treatment options, including advanced therapies for complex cases, such as large or impacted stones. With the growing number of individuals seeking medical care for stone diseases, hospitals are likely to remain the dominant end-user segment in the urolithiasis management devices market. Moreover, the continuous development of minimally invasive techniques in hospital settings is expected to further bolster the adoption of devices like ESWL and ureteroscopy, ensuring that hospitals continue to drive the largest share of the market.

North America Is Largest Region Due to Advanced Healthcare Systems

North America is the largest region in the urolithiasis management devices market, primarily due to its advanced healthcare infrastructure, high healthcare spending, and widespread access to cutting-edge medical technologies. The United States and Canada are key contributors to the region’s dominance, with a high rate of urolithiasis diagnosis and treatment. The region also benefits from strong healthcare policies and a well-established reimbursement system that supports the adoption of advanced medical devices, including those used for the treatment of kidney and bladder stones.

North America has seen significant investments in the development of minimally invasive technologies, such as advanced ESWL systems and flexible ureteroscopes, which have become the gold standard in urolithiasis management. As the incidence of kidney stones continues to rise due to factors such as diet, obesity, and lifestyle, North America’s healthcare system is well-positioned to meet the growing demand for effective stone management treatments. The region’s market leadership is expected to continue, supported by ongoing technological advancements and the continued adoption of non-invasive treatments for urolithiasis.

Leading Companies and Competitive Landscape

The urolithiasis management devices market is competitive, with key players such as Boston Scientific, Cook Medical, Olympus Corporation, Medtronic, and Conmed Corporation leading the way. These companies are at the forefront of developing and manufacturing advanced devices for the treatment of kidney and bladder stones.

The competitive landscape is shaped by continuous innovation in device technology, with a focus on improving the safety, efficiency, and patient comfort of urolithiasis management procedures. Leading companies are investing in research and development to create new, minimally invasive solutions, such as advanced ureteroscopy systems and more efficient shockwave lithotripters. Additionally, strategic partnerships and acquisitions are common in the market as companies aim to expand their product portfolios and enhance their market share. As demand for less invasive treatments grows, competition in the urolithiasis management devices market is expected to intensify, driving further innovation and improvement in patient care.

Recent Developments:

• Boston Scientific introduced an advanced ureteroscope with enhanced visualization and flexibility for kidney stone treatment.
• Olympus launched a new line of single-use nephroscopes, emphasizing infection control and precision.
• Karl Storz announced a strategic partnership with a urology-focused research institute to develop next-gen lithotripsy devices.
• Cook Medical expanded its portfolio with innovative stone removal baskets designed for enhanced maneuverability.
• Richard Wolf GmbH unveiled an upgraded lithotripter with AI-powered energy modulation for precise kidney stone targeting.

List of Leading Companies:

• Boston Scientific Corporation
• Johnson & Johnson Services, Inc.
• Medtronic plc
• Siemens Healthineers
• Cook Medical
• Fresenius Medical Care AG & Co. KGaA
• Teleflex Incorporated
• Stryker Corporation
• ConvaTec Group Plc
• Olympus Corporation
• Urotech Medical Ltd.
• Richard Wolf GmbH
• B. Braun Melsungen AG
• Hoya Corporation
• Shree Umiya Industries

Report Scope: